Bio-Path provides 2025 clinical update; plans IND for obesity drug, advances AML & solid tumor trials

BIO-PATH HOLDINGS, INC.

Prexigebersen Phase 2 AML trial: biomarker package to identify responders; expects completion of Cohort 2 & interim analysis for Cohort 3 in 2025.
BP1001-A Phase 1/1b solid tumors advanced to second dose cohort; one patient had 15% tumor reduction after 9 cycles; second/third cohorts expected to complete 2025.
BP1002 Phase 1/1b relapsed/refractory AML: third dose cohort (60 mg/m2) enrollment closed faster than expected; no dose limiting toxicities.
New preclinical program: BP1001-A for obesity in Type 2 diabetes; expects to file IND in 2025 after completing preclinical testing.
Patent portfolio includes 7 US patents, 61 foreign patents, and multiple applications pending worldwide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.